Nanjing Huanglong Biotechnology Co., Ltd. announced that it will raise CNY 30 million in a equity round of funding on April 24, 2024. The transaction will include participation from returning investor Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to retain its 100% stake in the company. The transaction has been approved by the board of directors of the investor company in the 24th meeting of the 8th board of directors.

The register capital will increase from CNY 110 million to CNY 140 million, post completion of the transaction.